In Brief: Pepcid AC Canadian launch
This article was originally published in The Tan Sheet
Pepcid AC Canadian launch: J&J/Merck announces the debut of Pepcid AC in Canada on June 25. Pepcid AC is "the first H2 receptor antagonist to become available without a prescription in Canada and the first new product to emerge from J&J/Merck Consumer Pharmaceuticals of Canada," according to the company. The Canadian joint venture was formed earlier this year ("The Tan Sheet" Feb. 5, p. 1). SmithKline Beecham's Tagamet HB is in "the final stages" of approval in the Canadian regulatory system and launch is "imminent," the company reports...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC